NorthernLight Diagnostics

At best 1/3 patients with depression respond to the first line antidepressant drugs. We are developing a biomarker to predict the response to antidepressant therapy before treatment initiation. This will dramatically shorten the suffering for patients and reduce the burden of disease and the costs for healthcare.